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Abstract
Background Infliximab-induced hepatotoxicity is repor-
ted in several case studies involving patients with inflam-
matory bowel disease (IBD) and a direct hepatotoxic effect
has been proposed.
Objective The aim of this study was to determine the
direct in vitro toxicity of infliximab. As a proof of principle
the in vitro toxicity of thiopurines and methotrexate was
also determined.
Methods Cell survival curves and the half maximal
inhibitory concentrations (IC50) were obtained after 24, 48
and 72 h of incubation in HepG2 cells with the IBD drugs
azathioprine, 6-mercaptopurine, 6-thioguanine, methotrex-
ate or infliximab by using the WST-1 cytotoxicity assay.
Results No in vitro hepatotoxicity in HepG2 cells was
seen with infliximab, while concentration-dependent cyto-
toxicity was observed when HepG2 cells were incubated
with increasing concentrations of azathioprine, 6-mercap-
topurine and 6-thioguanine.
Conclusion Infliximab alone or given in combination
with azathioprine showed no direct hepatotoxic effect in
vitro, indicating that the postulated direct hepatotoxicity of
infliximab is unlikely.
Keywords Inflammatory bowel disease  Hepatotoxicity 
HepG2 cells  Infliximab  Methotrexate  Azathioprine 
6-mercaptopurine  6-thioguanine
Abbreviations
IBD Inflammatory bowel disease
CD Crohn’s disease
UC Ulcerative colitis
TNF-a Tumour necrosis factor alpha
Introduction
Hepatotoxicity is defined as injury to the liver that is
associated with impaired liver function caused by exposure
to a drug or another noninfectious agent [1]. It is a serious
complication, frequently observed in the medical treatment
of inflammatory bowel disease (IBD) [2]. It can be directly
attributed to the type of drugs used to treat IBD, such
as immunosuppressants or biological therapies targeting
TNF-a. However, hepatotoxicity may also result from
drugs used to treat complications of immunosuppressants
and TNF-a antagonists, e.g. isoniazid for the treatment
of reactivation tuberculosis, or may be a result of exacer-
bation of underlying chronic viral hepatitis caused by
immunosuppression [3].
In December 2004, the Food and Drug Administration
(FDA) issued a drug warning to alert health care profes-
sionals to the risk of hepatotoxicity linked to infliximab [4].
However, severe hepatic reactions, including acute liver
failure, jaundice, hepatitis or cholestasis have rarely been
reported in patients receiving infliximab [5–8]. Further-
more, as demonstrated by Sokolove et al. [6] elevations of
serum transamines in patients receiving biological therapy
are uncommon and abnormalities of more than two times
the upper limit of normal are rarely observed. The mech-
anism of infliximab-induced hepatotoxicity is poorly
understood, although a direct hepatoxic effect has been
proposed by several authors [6–8]. To our knowledge, no in
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vivo or in vitro results supporting this hypothesis have been
reported.
The aim of this study was to determine the in vitro
hepatotoxicity of infliximab. As a proof of principle,
the conventional IBD medication, i.e. the thiopurines
azathioprine, 6-mercaptopurine and 6-thioguanine and
methotrexate, which are all known to be hepatotoxic, were
also tested. Although cultures of primary human hepato-
cytes seem to have the most relevant physiological prop-
erties for the evaluation of in vitro IBD drug hepatotoxicity,
they are difficult to obtain and rapidly lose their metabolic
properties [9]. Therefore, we used a human liver hepato-
cellular carcinoma (HepG2) cell line, which is very stable,
easy to handle and previously used in drug toxicity studies
[9]. HepG2 cells were incubated with increasing concen-
trations of infliximab, methotrexate or thiopurines for 24, 48
or 72 h and subsequently cell viability was determined.
Materials and Methods
Cell Culture
Human hepatocellular carcinoma (HepG2) cells (American
Type Culture Collection, Rockville, Maryland, USA) were
grown in Dulbecco’s Modified Eagle Medium (DMEM,
PAA Laboratories GmbH, Pasching, Austria) containing
10 % (v/v) heat-inactivated fetal bovine serum (Gibco
Invitrogen, Paisley, Scotland), 1X non-essential amino
acids (PAA), 20 mM HEPES buffer (PAA) and 50 mg/l
gentamycin (Gibco) at 37 C in a humidified atmosphere
containing 5 % CO2. The medium was renewed every
3 days and when confluence was reached, cells were har-
vested with trypsin/EDTA (Cambrex, Verviers, Belgium),
washed with phosphate-buffered saline, and used for
cytotoxicity assays.
Cytotoxicity Assays
HepG2 cells were seeded in flat-bottomed 96-well micro-
titre plates (Costar; Corning Inc., Corning, New York,
USA) at a density of 5.0 9 104 cells per well in a final
volume of 100 ll culture medium, and cells were cultured
for 24 h. Subsequently, cells were incubated with the single
drugs azathioprine, 6-mercaptopurine, methotrexate (all
Sigma-Aldrich Chemie B.V., Zwijndrecht, The Nether-
lands), 6-thioguanine (Alfa Aesar GmbH & Co KG,
Karlsruhe, Germany) or infliximab (Remicade, Centocor,
Leiden, the Netherlands) for 24, 48 and 72 h. The following
concentration series were used: azathioprine: 0.002 lM–
4 mM; 6-mercaptopurine: 0.002–200 lM; 6-thioguanine:
0.002 lM–4 mM; methotrexate: 50 nM–100 lM; inflix-
imab: 0.002 mg/l–5 g/l.
In subsequent experiments the cytotoxicity of a combi-
nation of drugs was tested. A single, non-toxic concentra-
tion of azathioprine (1 lM) was tested in combination with
a concentration range of infliximab (0.002 mg/l–5 g/l),
whereas a single, non-toxic concentration of infliximab
(312 mg/l) was tested in combination with a concentration
range of azathioprine (0.002 lM–4 mM).
All drugs were first dissolved in 0.1 M NaOH and then
rapidly diluted in the culture medium to reach the final
concentration. A refreshment of the culture medium with
the various concentrations of drugs was done every 24 h.
After the incubation with drugs, a cell survival assessment
was performed by adding water-soluble tetrazolium salt-1
(WST-1, Roche Diagnostics Nederland BV, Almere, The
Netherlands) according to the manufacturer’s instructions.
In the WST-1 assay, tetrazolium salts are cleaved by
dehydrogenases of viable cells to produce formazan. The
amount of formazan dye was quantified by using an ELISA
plate reader at 440 nm. Cell survival was defined as:
Cell survival ¼ Aexperimental  Abackground
Acontrol  Abackground  100%
where Aexperimental is the absorbance of drug incubated cells
plus WST-1, Abackground is the absorbance of culture med-
ium plus WST-1 in the absence of cells and Acontrol is the
absorbance of cells without drugs plus WST-1. Test results
were obtained from three independent experiments, each
performed in triplicate.
Statistics
One-way ANOVA analysis was used to compare the effect
of incubation time. A p-value \0.05 was considered sta-
tistically significant. Data were normalized to untreated
cells using GraphPad Prism to calculate the concentration
at which cell survival is 50 % (IC50, i.e. half maximal
inhibitory concentrations). All statistical analyses and cal-
culations were carried out using GraphPad Prism (version
4.0; GraphPad Software, San Diego, California, USA).
Results
The incubation of HepG2 cells with increasing concentra-
tions of infliximab did not result in significant changes in
cell viability, indicating that a direct in vitro cytotoxic
effect was absent (Fig. 1). At all concentrations of inflix-
imab tested after 24, 48 or 72 h of incubation, cell survival
was above 50 % and no IC50 values could be determined
(Table 1). Only at the highest concentration of 5 g/l, could
a decrease of about 30 % in cell survival could be seen
(Fig. 1). Concentration-dependent cytotoxicity was clearly
observed when HepG2 cells were incubated with
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increasing concentrations of azathioprine, 6-mercaptopur-
ine or 6-thioguanine (Fig. 2). Only methotrexate showed a
time-dependent cytotoxic effect on HepG2 cells. Incuba-
tion with various concentrations of methotrexate for 72 h
resulted in a significant difference when compared to 24 h
of incubation (p \ 0.01).
After 24 h of incubation, neither the combination of
infliximab (0.002 mg/l–5 g/l) with a low dose (1 lM) of
azathioprine nor the combination of a single, non-toxic
concentration of infliximab (312 mg/l) in combination with
azathioprine (0.002 lM–4 mM) showed any difference in
cell survival (data not shown).
Discussion
In this study infliximab showed no direct cytotoxic effect on
HepG2 cells, even at concentrations far exceeding the
maximum concentration of 118 lg/ml, which infliximab
achieves when administered intravenously at a dosage of
5 mg/kg [10]. Concomitant incubation with both inflix-
imab in different dosages and azathioprine at a non toxic
concentration did not alter HepG2 cell viability. Our in vitro
results therefore suggest that a direct hepatotoxicity of
infliximab is implausible. Alternatively, infliximab-induced
hepatotoxicity is more likely to be immuno-mediated or
induced via Fc receptor-mediated interactions. After form-
ing an immune complex with TNF-a, this complex is
cleared by the mononuclear phagocytic system in the liver
via Fc receptor-mediated interactions that in turn can acti-
vate Kupffer cells. These resident macrophages of the liver
located in hepatic sinusoids do release reactive oxygen
species which may lead to local damage of hepatocytes
[11–13]. During infliximab therapy, increased formation of
anti-nuclear antibodies has been observed [14], most pos-
sibly due to the fact that binding of infliximab to trans-
membrane TNF on the cell surface induces apoptosis,
leading to the release of nucleosomes and the generation of
anti-nuclear antibodies [15]. Since antibodies to TNF-a
delay the repair of liver injury [16, 17], the use of infliximab
might also exacerbate a previous suboptimal liver condition
not recognized by any clinical symptoms or biochemical
markers. Furthermore, a potential hepato-protective effect
of TNF-a induced by increasing hepatocyte regeneration
and decreasing apoptosis has been observed in a transgenic
mouse model of chronic hepatitis C while treatment with
anti-TNF-a blocked the anti-apoptotic and regenerative
effects induced by TNF-a [18].
In contrast to our experience with infliximab, we
observed a concentration dependent cytotoxic effect of the
thiopurines in HepG2 cells, while methotrexate demon-
strated a time- and concentration-dependent effect. The in
vitro hepatotoxic effects of thiopurines have also been
demonstrated by Petit et al., comparing the cytotoxicity of
thiopurines in human hepatocytes and HepaRG cells,
incubated for 24, 48, 72 and 96 h with 1, 5 or 25 lM of
azathioprine, 6-mercaptopurine or 6-thioguanine. They
reported a dose- and time-dependent cytotoxic effect of
azathioprine and 6-mercaptopurine in both human hepato-
cytes and HepRG cells, while 6-thioguanine had no sig-
nificant effect on human hepatocytes. However, 72 h of
incubation with either 5 or 25 lM of 6-thioguanine showed
a 30 % decrease in cell survival of HepaRG cells [19].
Fig. 1 Cell survival of HepG2 cells after exposure to various
concentrations of infliximab for 24, 48 or 72 h. Cell survival was
expressed as a percentage of untreated cells. Values are means ±
SEM of three independent experiments performed in triplicate
Table 1 Cytotoxicity of IBD drugs in HepG2 cells
Incubation IC50 (lM)
Azathioprine 6-Mercaptopurine 6-Thioguanine Methotrexate Infliximab
24 h 33.7 ± 29.3 3.8 ± 4.1 1.1 ± 0.8 NA NA
48 h 0.5 ± 0.3 0.5 ± 0.6 0.4 ± 0.5 9.3 ± 16.0 NA
72 h 0.9 ± 0.6 0.4 ± 0.3 0.5 ± 0.7 0.04 ± 0.03 NA
IBD inflammatory bowel disease, NA not applicable (IC50 value was not reached), SD standard deviation, IC50 half maximal inhibitory
concentrations
Values are mean IC50 ± SD (n = 9) derived after normalization of dose response curves using Graphpad Prism
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The observed time-dependent cytotoxic effect of meth-
otrexate in our study is in line with results of Yin et al. [20]
who reported a time- and concentration-dependent effect of
high dose methotrexate (1–10 mM) in rat hepatocytes.
These concentrations however go far beyond the mean
peak concentration in human plasma of 1.14 lM achieved
after subcutaneous administration of 15 mg methotrexate
to patients with IBD [21].
Several limitations of our study should be noticed. First
of all, results of in vitro studies cannot be directly
extrapolated to the in vivo situation. Isolated liver (carci-
noma) cells will respond differently to stress or toxic
compounds than to an intact and perfused liver. Therefore,
although results from cell lines add to the understanding of
drug-induced toxicity, they will be difficult to translate
into clinical practice. Processes of absorption, distribution,
metabolism and excretion, which determine the exposure
of the target tissues of an organism in vivo, are mainly
absent in in vitro studies [22]. Furthermore, peripheral
serum or plasma concentrations do not reflect the
concentrations in the portal vein. Therefore the drug
concentrations to which the liver is actually exposed are
largely unknown. These points are especially true for the
thiopurines. Resorption is highly variable in animal studies
as well as in patients with inflammatory bowel disease and
the pro-drugs azathioprine and 6-mercaptopurine are rap-
idly converted [23–26]. Additionally, as in hepatocytes in
the primary culture, changes in the expression of drug
metabolizing enzymes over time occur in HepG2 cells
[27]. Therefore neither primary cultures of hepatocytes nor
HepG2 cells display an ideal model mimicking the
expression levels of drug metabolizing enzymes as present
in hepatocytes in vivo, thereby limiting the reproducibility
of in vitro hepatotoxicity experiments using different cell
cultures [27]. In our study we focused on cell viability as a
marker of hepatotoxicity. Alterations in pathways under-
lying cell death including oxidative stress were not
studied.
Fig. 2 Effect of thiopurines and methotrexate on HepG2 cell
viability. HepG2 cells were incubated with various concentrations
of IBD drugs for 24, 48 or 72 h and cell survival was measured and
expressed as percentage of untreated cells. The graphs summarize the
results of three independent experiments (means ± SEM), performed
in triplicate
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In conclusion, our study suggests that infliximab does
not have a direct toxic effect on HepG2 cells. In addition,
infliximab in combination with thiopurines does not
increase their in vitro toxicity on HepG2 cells. Our results
may not be translated to clinical practice directly without
considering the limitations of these findings. On the other
hand, no alarming cytotoxicity is seen in the same assay
that shows evident dose-related thiopurine cytotoxicity.
Future studies regarding the hepatotoxic effects of inflix-
imab should focus on Fc receptor-mediated interactions
and auto-immune related factors.
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